• Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)
    • Services
      • Equity Reports (Analyst-Ready)
      • Visibility Upgrades (Quartely + As needed)
      • Investor Mapping
    • Press
    • Contact
    • English
      • Deutsch (German)
      • 日本語 (Japanese)
  • info@vasro.net
  • +49 (0)69 90 28 39 81
  • Call us Mon - Fri: 8:30 AM - 6:00 PM
VASRO GmbH
VASRO GmbH
  • Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)

long-term investing

VASRO GmbH > Press > long-term investing
VASRO GmbH

Galaxy Digital achieves Nasdaq listing, marking a new era in growth strategy

  • May 22, 2025
  • Unkategorisiert
Galaxy Digital's Nasdaq listing boosts its U.S. visibility, attracting investors and solidifying its growth strategy in cryptocurrency and artificial intelligence.
Continue Reading
VASRO GmbH

How Equity Analysis Enhances Tech Stock Valuation

  • May 14, 2025
  • Tech
Equity analysis bridges market trends and intrinsic value, offering data-driven insights to accurately value tech stocks and navigate market volatility.
Continue Reading

Search

Categories

  • Energy
  • Equity Analysis reports
  • Equity Research Coverage
  • Market Intelligence
  • Pharma & Biotech
  • Tech
  • Unkategorisiert

Recent Posts

Ainos, Inc.: Three Patents Approved in Japan, and a Dataset Gathering Pace September 11, 2026
Baladna: The Capital Is Raised, Algeria Is Building – VASRO Reiterates BUY at QAR 2.33 September 7, 2026
Sirnaomics Ltd.: Every Approved siRNA Drug Works in the Liver. This One Was Injected Into Skin Cancer. VASRO Initiates Coverage With BUY September 7, 2026
Zaptec ASA: Europe’s Largest AC Charging Brand, With the Service Layer Priced at Zero – VASRO Initiates Coverage With BUY August 31, 2026
Spinneys 1961 Holding PLC: The Estate Grew 17%, Demand Did Not — First Half 2026 Update August 12, 2026
VASRO GmbH
VASRO GmbH specializes in equity analysis, market intelligence, and investment strategy for the pharmaceutical, biotechnology, and IT sectors. We deliver tailored insights to drive informed investment decisions and achieve exceptional results.

Discover More

Contact Info

  • Am Hauptbahnhof 16, 60329 Frankfurt am Main, Germany
  • +49 (0)69 90 28 39 81
  • Info@vasro.net
  • 8:30 AM - 6:00 PM

Navigation

  • Imprint
  • Privacy Policy
  • Change privacy settings
  • Application
  • About
  • FAQ

©copyright 2025 VASRO GmbH.